Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.75.

Several brokerages have commented on AUTL. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 17th. HC Wainwright upped their price objective on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Mizuho dropped their target price on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Independent Advisor Alliance purchased a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $28,000. Marex Group plc purchased a new position in Autolus Therapeutics during the second quarter valued at $28,000. Waverly Advisors LLC bought a new stake in Autolus Therapeutics during the first quarter valued at about $37,000. SmartHarvest Portfolios LLC purchased a new stake in Autolus Therapeutics in the fourth quarter worth about $43,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics in the third quarter worth about $46,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

NASDAQ:AUTL traded down $0.01 during trading hours on Tuesday, hitting $1.62. The company had a trading volume of 318,680 shares, compared to its average volume of 1,629,853. Autolus Therapeutics has a 52 week low of $1.18 and a 52 week high of $2.70. The company has a market capitalization of $432.51 million, a PE ratio of -1.49 and a beta of 2.04. The stock has a 50-day moving average price of $1.60 and a 200 day moving average price of $1.56.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The company had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. Analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.